Vinva Investment Management Ltd Has $17.99 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Vinva Investment Management Ltd raised its stake in Johnson & Johnson (NYSE:JNJ) by 6.8% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 111,448 shares of the company’s stock after purchasing an additional 7,110 shares during the quarter. Johnson & Johnson makes up about 0.8% of Vinva Investment Management Ltd’s portfolio, making the stock its 20th biggest holding. Vinva Investment Management Ltd’s holdings in Johnson & Johnson were worth $17,988,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Strategic Wealth Partners Ltd. raised its stake in Johnson & Johnson by 26.7% in the 1st quarter. Strategic Wealth Partners Ltd. now owns 6,077 shares of the company’s stock valued at $961,000 after acquiring an additional 1,280 shares during the period. Raelipskie Partnership increased its holdings in shares of Johnson & Johnson by 3.9% in the first quarter. Raelipskie Partnership now owns 14,090 shares of the company’s stock valued at $2,229,000 after purchasing an additional 531 shares during the last quarter. Community Trust & Investment Co. raised its position in shares of Johnson & Johnson by 0.9% in the first quarter. Community Trust & Investment Co. now owns 96,066 shares of the company’s stock valued at $15,197,000 after purchasing an additional 877 shares during the period. Cetera Investment Advisers lifted its stake in shares of Johnson & Johnson by 224.0% during the 1st quarter. Cetera Investment Advisers now owns 707,273 shares of the company’s stock worth $111,884,000 after buying an additional 488,955 shares during the last quarter. Finally, Cetera Advisors LLC grew its stake in Johnson & Johnson by 71.6% in the 1st quarter. Cetera Advisors LLC now owns 274,630 shares of the company’s stock valued at $43,444,000 after buying an additional 114,547 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on JNJ. Wells Fargo & Company raised their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Morgan Stanley boosted their price target on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Guggenheim boosted their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Finally, Citigroup raised their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $175.94.

Johnson & Johnson Trading Up 0.6 %

Shares of JNJ stock opened at $155.39 on Thursday. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The stock’s fifty day moving average price is $159.52 and its two-hundred day moving average price is $156.38. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company has a market cap of $374.12 billion, a PE ratio of 22.49, a P/E/G ratio of 2.77 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson’s revenue was up 5.2% compared to the same quarter last year. During the same period last year, the firm posted $2.66 earnings per share. Equities analysts predict that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.19%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s payout ratio is 71.78%.

Insiders Place Their Bets

In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The trade was a 22.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.